New drug combo targets Hard-to-Treat ovarian and endometrial cancers
NCT ID NCT05950464
First seen Sep 30, 2025 · Last updated Jun 17, 2026 · Updated 41 times
Summary
This early-phase trial is testing a combination of two drugs, M1774 and ZEN-3694, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the combination can slow or stop cancer growth by blocking key enzymes. About 65 adults with specific types of recurrent cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Augusta University Medical Center
SUSPENDEDAugusta, Georgia, 30912, United States
-
Case Western Reserve University
ACTIVE_NOT_RECRUITINGCleveland, Ohio, 44106, United States
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-••••
Contact
-
NRG Oncology
RECRUITINGPhiladelphia, Pennsylvania, 19103, United States
Contact Email: •••••@•••••
Contact
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Iowa/Holden Comprehensive Cancer Center
RECRUITINGIowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-••••
-
University of New Mexico Cancer Center
RECRUITINGAlbuquerque, New Mexico, 87106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania/Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wayne State University/Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Women and Infants Hospital
RECRUITINGProvidence, Rhode Island, 02905, United States
Contact
Contact Phone: •••-•••-••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.